ArticleAbdominal radiology (New York)2026
MRI-based habitat radiomics for assessing synchronous metastatic risk in renal cell carcinoma: a multicenter study.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
purposeTo explore the role of MRI-based habitat radiomics in assessing the metastatic status of renal cell carcinoma (RCC).
methodsThis study retrospectively collected 241 patients with RCC who underwent nephrectomy and lymphadenectomy at four centers. MRI data from the first center were split into a training set (n = 150) and an internal test set (n = 38); data from the other centers (n = 53) were used for external testing. Based on corticomedullary-phase enhancement and T2WI signal intensity, primary lesions were segmented into 15 habitat subregions. Radiomic features were extracted from the whole-tumor and habitat subregions, respectively. Machine learning algorithms were employed to construct models. Clinical indicators were then integrated to establish a combined model, with performance comparisons and subgroup analyses conducted based on both the internal and external test sets.
resultsAmong the 241 patients (mean age 53 ± 13 years; 169 males), 36.1% exhibited distant or regional lymph node (RLN) metastases. The habitat models generally achieved higher area under the curves (AUCs) compared with the whole-tumor models in the internal and external test sets. By incorporating RLN size, the combined model outperformed the habitat model in the internal test set (AUC, 0.88 vs. 0.82, P = 0.020) and the clinical model integrating RLN size and hematuria in the external test set (AUC, 0.89 vs. 0.73, P = 0.012). Subgroup analyses showed that the combined model could independently identify distant and RLN metastases, unaffected by pathological subtypes.
conclusionMRI-based habitat radiomics model provides a non-invasive tool for accurately assessing metastatic status in RCC.
Indexed as
Identifiers
41711878What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.